Essec\Faculty\Model\Contribution {#2233
  #_index: "academ_contributions"
  #_id: "889"
  #_source: array:26 [
    "id" => "889"
    "slug" => "cost-of-non-persistence-with-oral-biphosphonates-in-post-menopausal-osteoporosis-treatment-in-france"
    "yearMonth" => "2011-06"
    "year" => "2011"
    "title" => "Cost of Non-Persistence with Oral Biphosphonates in Post-Menopausal Osteoporosis Treatment in France"
    "description" => "COTTE, F.E. et PUYOU DE POUVOURVILLE, G. (2011). Cost of Non-Persistence with Oral Biphosphonates in Post-Menopausal Osteoporosis Treatment in France. <i>BMC Health Services Research</i>, 151(11), pp. 1-10."
    "authors" => array:2 [
      0 => array:3 [
        "name" => "PUYOU DE POUVOURVILLE Gérard"
        "bid" => "B00072308"
        "slug" => "de-pouvourville-gerard"
      ]
      1 => array:1 [
        "name" => "COTTE F.-E."
      ]
    ]
    "ouvrage" => ""
    "keywords" => array:6 [
      0 => "Osteoporosis"
      1 => "Bisphosphonate"
      2 => "Adherence"
      3 => "Persistence"
      4 => "Cost"
      5 => "Modelling study"
    ]
    "updatedAt" => "2021-02-02 16:16:18"
    "publicationUrl" => "https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-11-151"
    "publicationInfo" => array:3 [
      "pages" => "1-10"
      "volume" => "151"
      "number" => "11"
    ]
    "type" => array:2 [
      "fr" => "Articles"
      "en" => "Journal articles"
    ]
    "support_type" => array:2 [
      "fr" => "Revue scientifique"
      "en" => "Scientific journal"
    ]
    "countries" => array:2 [
      "fr" => null
      "en" => null
    ]
    "abstract" => array:2 [
      "fr" => "Pendant la dernière décennie, les biphosphonates sont devenus le traitement de référence de l'ostéoporose. Cependant, de nombreuses études montrent que la persistance sous traitement est faible et diminue leur efficacité préventive. L'étude a estimé l'impact de cette faible persistance sur le coût de prise en charge de l'ostéoporose en France."
      "en" => "During the last decade, oral biphosphonates (BP) became the most widely prescribed pharmacologic class for post-menopausal osteoporosis. However, many surveys revealed the important issue of poor persistence with those drugs resulting in a failure of treatment to reduce fracture risk sufficiently. Using a published Markov model, this study analyses the economic impact of non-persistence with biphosphonates in the context of the introduction of generics in France."
    ]
    "authors_fields" => array:2 [
      "fr" => "Management"
      "en" => "Management"
    ]
    "indexedAt" => "2024-11-22T06:21:50.000Z"
    "docTitle" => "Cost of Non-Persistence with Oral Biphosphonates in Post-Menopausal Osteoporosis Treatment in France"
    "docSurtitle" => "Articles"
    "authorNames" => "<a href="/cv/de-pouvourville-gerard">PUYOU DE POUVOURVILLE Gérard</a>, COTTE F.-E."
    "docDescription" => "<span class="document-property-authors">PUYOU DE POUVOURVILLE Gérard, COTTE F.-E.</span><br><span class="document-property-authors_fields">Management</span> | <span class="document-property-year">2011</span>"
    "keywordList" => "<a href="#">Osteoporosis</a>, <a href="#">Bisphosphonate</a>, <a href="#">Adherence</a>, <a href="#">Persistence</a>, <a href="#">Cost</a>, <a href="#">Modelling study</a>"
    "docPreview" => "<b>Cost of Non-Persistence with Oral Biphosphonates in Post-Menopausal Osteoporosis Treatment in France</b><br><span>2011-06 | Articles </span>"
    "docType" => "research"
    "publicationLink" => "<a href="https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-11-151" target="_blank">Cost of Non-Persistence with Oral Biphosphonates in Post-Menopausal Osteoporosis Treatment in France</a>"
  ]
  +lang: "fr"
  +"_type": "_doc"
  +"_score": 9.0641575
  +"parent": null
}